Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01620515 · ClinicalTrials.gov registry record · Phase 2

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Nymox Corporation.

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 2
Development phase: 141
Enrollment target: 20
Study locations

NCT01620515: Completed Phase 2 study of Prostate Cancer, sponsored by Nymox Corporation.

NCT01620515 is a Phase 2 study of Prostate Cancer that has completed, run by Nymox Corporation. The registered enrollment target is 141 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01620515, a Phase 2 study of Prostate Cancer, has completed, sponsored by Nymox Corporation.

COMPLETED
Registry status: Phase 2
Development phase: 141 participants
Enrollment target: 20
Study locations

Study Summary

This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance. Study participants currently on active surveillance will be randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5 mg or 15 mg) followed by active surveillance or to no treatment (continued active surveillance). Blinded efficacy evaluation will be by a second post-treatment prostate biopsy.

Primary Outcome

The primary efficacy endpoint is the percentage of subjects with undetectable prostate cancer (negative biopsy) in the region of the prostate where the baseline cancer was detected.

Conditions Studied

Prostate Cancer

Interventions

DRUG NX-1207 2.5 mg
DRUG NX-1207 15 mg

Study Locations (20)

California 4 sites (20%) Colorado 2 sites (10%) Florida 2 sites (10%) Maryland 2 sites (10%) New York 2 sites (10%) Other 8 sites (40%)

California

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Atherton
For information concerning this clinical site, please contact Nymox at 800-936-9669. - La Mesa
For information concerning this clinical site, please contact Nymox at 800-936-9669. - Long Beach
For information concerning this clinical site, please contact Nymox at 800-936-9669. - San Diego

Colorado

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Denver
For information concerning this clinical site, please contact Nymox at 800-936-9669. - Englewood

Florida

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Aventura
For information concerning this clinical site, please contact Nymox at 800-936-9669. - Naples

Maryland

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Annapolis
For information concerning this clinical site, please contact Nymox at 800-936-9669. - Baltimore

New York

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Garden City
For information concerning this clinical site, please contact Nymox at 800-936-9669. - New York

Arizona

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Tucson

Connecticut

For information concerning this clinical site, please contact Nymox at 800-936-9669. - New Britain

Indiana

For information concerning this clinical site, please contact Nymox at 800-936-9669. - Jeffersonville

Trial Details

Field	Value
Enrollment Target	141 participants
Start Date	2012-02-21
Est. Completion	2015-10-21
Phase	Phase 2

Nymox Corporation

6 total trials

What the finished NCT01620515 record still lists

NCT01620515 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which NX-1207 2.5 mg is the first listed.

NCT01620515 names 20 study sites across 13 states, led by California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01620515 about?

NCT01620515 is a clinical study titled "Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer". This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance. Study participants currently on active surveillance will be randomized eith...

What is the current status of trial NCT01620515?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2012-02-21. Estimated completion is 2015-10-21.

What conditions does trial NCT01620515 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01620515?

The interventions under investigation include: NX-1207 2.5 mg (DRUG), NX-1207 15 mg (DRUG).

Who is sponsoring clinical trial NCT01620515?

This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01620515 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01620515's enrollment target sits among peer trials

141 278th of 735 higher than 458 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT03042962 · 141 participants
Brain Networks in Dystonia
NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01620515, the US trial registry maintained by the National Library of Medicine. NCT01620515 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.